Having trouble accessing articles? Reset your cache.

Abbisko builds combination strategy with China rights to X4's mavorixafor

Abbisko has licensed Greater China rights to X4’s mavorixafor, which the Shanghai-based company plans to use to develop a pipeline of combination therapies.

The deal, for which financial terms are not disclosed, gives Abbisko Therapeutics Co. Ltd. exclusive

Read the full 385 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers